1 Hernandez AV, "Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials" 11 : 115-128, 2011
2 Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea" 29 : 744-751, 2011
3 Hiatt WR, "The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience" 369 : 1285-1287, 2013
4 McMurray J, "The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial" European Society of Cardiology 99-, 2013
5 Weir DL, "Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study" 2 : 573-582, 2014
6 Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus" 369 : 1317-1326, 2013
7 Nissen SE, "Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality" 170 : 1191-1201, 2010
8 Marney A, "Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans" 56 : 728-733, 2010
9 Skyler JS, "Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association" 32 : 187-192, 2009
10 Nathan DM, "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes" 353 : 2643-2653, 2005
1 Hernandez AV, "Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and metaregression analysis of placebo-controlled randomized clinical trials" 11 : 115-128, 2011
2 Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea" 29 : 744-751, 2011
3 Hiatt WR, "The cardiovascular safety of diabetes drugs: insights from the rosiglitazone experience" 369 : 1285-1287, 2013
4 McMurray J, "The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDD) trial" European Society of Cardiology 99-, 2013
5 Weir DL, "Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study" 2 : 573-582, 2014
6 Scirica BM, "Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus" 369 : 1317-1326, 2013
7 Nissen SE, "Rosiglitazone revisited: an updated metaanalysis of risk for myocardial infarction and cardiovascular mortality" 170 : 1191-1201, 2010
8 Marney A, "Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans" 56 : 728-733, 2010
9 Skyler JS, "Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association" 32 : 187-192, 2009
10 Nathan DM, "Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes" 353 : 2643-2653, 2005
11 Laakso M, "Insulin resistance and hyperglycaemia in cardiovascular disease development" 10 : 293-302, 2014
12 Krum H, "Heart failure and dipeptidyl peptidase-4 inhibitors" 16 : 603-607, 2014
13 Ban K, "Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39)yet does not require the known GLP-1 receptor" 151 : 1520-1531, 2010
14 Gustavson SM, "Effects of a long-acting GLP-1mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus" 13 : 1056-1058, 2011
15 Sachdeva A, "Discontinuation of long-term clopidogrel therapy is associated with death and myocardial infarction after saphenous vein graft percutaneous coronary intervention" 60 : 2357-2363, 2012
16 Monami M, "Dipeptidyl peptidase-4inhibitors and heart failure: a meta-analysis of randomized clinical trials" 24 : 689-697, 2014
17 Monami M, "Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials" 15 : 112-120, 2013
18 Wu S, "Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants" 32 : 147-158, 2014
19 Scheen AJ, "Cardiovascular effects of gliptins" 10 : 73-84, 2013
20 Ussher JR, "Cardiovascular biology of the incretin system" 33 : 187-215, 2012
21 Defronzo RA, "Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus" 58 : 773-795, 2009
22 Stratton IM, "Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study" 321 : 405-412, 2000
23 Iqbal N, "Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials" 13 : 33-, 2014
24 Goldfine AB, "Assessing the cardiovascular safety of diabetes therapies" 359 : 1092-1095, 2008
25 Radford MJ, "American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Failure Society of America. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America" 112 : 1888-1916, 2005